Search

Your search keyword '"Rocca, B"' showing total 603 results
Start Over Author "Rocca, B"
603 results on '"Rocca, B"'

1. Longitudinal trajectories of psychosocial functioning in patients with pre-existing mental disorders after one year of COVID-19 pandemic

Author

Massoni e Debora Andreoli, Leonardo, Clesi, Francesca Maria, Bastanzetti, Vittoria, Longo, Paola, Panero, Matteo, Burato, Sofia, D'Aietti, Alberto, Faldi, Marco, Marchesoni, Giorgia, Di Vincenzo, Matteo, Tretola, Lucia, Possidente, Chiara, Cosentini, Nicola, Berardelli, Isabella, Erbuto, Denise, Luciano, M., Carmassi, C., Sampogna, G., Bertelloni, C.A., Abbate-Daga, G., Albert, U., Castellini, G., Della Rocca, B., Fantasia, S., Menchetti, M., Pedrinelli, V., Pompili, M., Signorelli, M.S., Tosato, S., and Fiorillo, A.

Published
2024
Full Text
View/download PDF

2. Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial

Author

Ostuzzi, G, Gastaldon, C, Tettamanti, M, Cartabia, M, Monti, I, Aguglia, A, Aguglia, E, Bartoli, F, Callegari, C, Canozzi, A, Carbone, E, Carrà, G, Caruso, R, Cavallotti, S, Chiappini, S, Colasante, F, Compri, B, D'Agostino, A, De Fazio, P, de Filippis, R, Gari, M, Ielmini, M, Ingrosso, G, Mammarella, S, Martinotti, G, Rodolico, A, Roncone, R, Sterzi, E, Tarsitani, L, Tiberto, E, Todini, L, Amaddeo, F, D'Avanzo, B, Barbato, A, Barbui, C, Alessi, M, Avincola, G, Bachi, B, Bernasconi, G, Birgillito, A, Bisso, E, Bonora, S, Calabrese, A, Callovini, T, Canestro, A, Canonico, S, Capogrosso, C, Carosielli, D, Caselli, I, Cavaleri, D, Cavallotto, C, Cesca, M, Chiarenza, C, Cioni, R, Coloccini, S, Cruciata, M, Cumerlato, C, De Filippis, R, De Palma, M, Del Vecchio, S, Della Rocca, B, Di Natale, C, D'Onofrio, E, Espa, I, Fior, G, Gancitano, M, Giordano, B, Giusti, L, Grassi, L, Guzzi, P, Isella, C, Lax, A, Marano, L, Marconi, F, Marella, M, Metelli, A, Michencig, G, Miuli, A, Moncada, A, Morello, P, Moretti, F, Morreale, M, Mosca, A, Nasti, C, Nosé, M, Ogheri, F, Oresti, M, Ornaghi, A, Palpella, D, Pancheri, C, Papola, D, Passeri, S, Pettorusso, M, Piacenti, S, Pinucci, I, Pugliese, V, Purgato, M, Rania, M, Robbi, F, Romito, S, Ronchi, B, Roselli, V, Segura-Garcia, C, Signorelli, M, Simonelli, G, Sociali, A, Sturiale, S, Tambelli, A, Todesco, B, Trabucco, A, Turrini, G, Villa, V, Wiedenmann, F, Zambuto, L, Zanini, E, Zannini, C, Zerbinati, L, Ostuzzi, Giovanni, Gastaldon, Chiara, Tettamanti, Mauro, Cartabia, Massimo, Monti, Igor, Aguglia, Andrea, Aguglia, Eugenio, Bartoli, Francesco, Callegari, Camilla, Canozzi, Andrea, Carbone, Elvira Anna, Carrà, Giuseppe, Caruso, Rosangela, Cavallotti, Simone, Chiappini, Stefania, Colasante, Fabrizio, Compri, Beatrice, D'Agostino, Armando, De Fazio, Pasquale, de Filippis, Renato, Gari, Matteo, Ielmini, Marta, Ingrosso, Gianmarco, Mammarella, Silvia, Martinotti, Giovanni, Rodolico, Alessandro, Roncone, Rita, Sterzi, Enrico, Tarsitani, Lorenzo, Tiberto, Elisa, Todini, Liliana, Amaddeo, Francesco, D'Avanzo, Barbara, Barbato, Angelo, Barbui, Corrado, Alessi, Maria Chiara, Avincola, Gabriele, Bachi, Bianca, Bernasconi, Gianna, Birgillito, Andrea, Bisso, Emanuele, Bonora, Stefano, Calabrese, Angela, Callovini, Tommaso, Canestro, Aurelia, Canonico, Salvo, Capogrosso, Chiara Alessandra, Carbone, Elvira, Carosielli, Doriana, Caselli, Ivano, Cavaleri, Daniele, Cavallotto, Clara, Cesca, Marco, Chiarenza, Cecilia, Cioni, Riccardo Matteo, Coloccini, Sara, Cruciata, Marco, Cumerlato, Claudia, De Filippis, Renato, De Palma, Manuela, Del Vecchio, Sasha, Della Rocca, Bianca, Di Natale, Chiara, D'Onofrio, Ettore, Espa, Irene, Fior, Giulia, Gancitano, Marta, Giordano, Barbara, Giusti, Laura, Grassi, Luigi, Guzzi, Pierluca, Isella, Celeste, Lax, Annamaria, Marano, Leonardo, Marconi, Federico, Marella, Marco, Metelli, Alessia, Michencig, Giulia, Miuli, Andrea, Moncada, Alessandro, Morello, Pietro, Moretti, Federico, Morreale, Marco, Mosca, Alessio, Nasti, Christian, Nosé, Michela, Ogheri, Filippo, Oresti, Margherita, Ornaghi, Alessandra, Palpella, Dario, Pancheri, Corinna, Papola, Davide, Passeri, Silvia, Pettorusso, Mauro, Piacenti, Susanna, Pinucci, Irene, Pugliese, Valentina, Purgato, Marianna, Rania, Marianna, Robbi, Federica, Romito, Samantha, Ronchi, Barbara, Roselli, Valentina, Segura-Garcia, Cristina, Signorelli, Maria Salvina, Simonelli, Gabriele, Sociali, Antonella, Sturiale, Serena, Tambelli, Antonio, Todesco, Beatrice, Trabucco, Alice, Turrini, Giulia, Villa, Veronica, Wiedenmann, Federico, Zambuto, Luca, Zanini, Elisa, Zannini, Chiara, Zerbinati, Luigi, Ostuzzi, G, Gastaldon, C, Tettamanti, M, Cartabia, M, Monti, I, Aguglia, A, Aguglia, E, Bartoli, F, Callegari, C, Canozzi, A, Carbone, E, Carrà, G, Caruso, R, Cavallotti, S, Chiappini, S, Colasante, F, Compri, B, D'Agostino, A, De Fazio, P, de Filippis, R, Gari, M, Ielmini, M, Ingrosso, G, Mammarella, S, Martinotti, G, Rodolico, A, Roncone, R, Sterzi, E, Tarsitani, L, Tiberto, E, Todini, L, Amaddeo, F, D'Avanzo, B, Barbato, A, Barbui, C, Alessi, M, Avincola, G, Bachi, B, Bernasconi, G, Birgillito, A, Bisso, E, Bonora, S, Calabrese, A, Callovini, T, Canestro, A, Canonico, S, Capogrosso, C, Carosielli, D, Caselli, I, Cavaleri, D, Cavallotto, C, Cesca, M, Chiarenza, C, Cioni, R, Coloccini, S, Cruciata, M, Cumerlato, C, De Filippis, R, De Palma, M, Del Vecchio, S, Della Rocca, B, Di Natale, C, D'Onofrio, E, Espa, I, Fior, G, Gancitano, M, Giordano, B, Giusti, L, Grassi, L, Guzzi, P, Isella, C, Lax, A, Marano, L, Marconi, F, Marella, M, Metelli, A, Michencig, G, Miuli, A, Moncada, A, Morello, P, Moretti, F, Morreale, M, Mosca, A, Nasti, C, Nosé, M, Ogheri, F, Oresti, M, Ornaghi, A, Palpella, D, Pancheri, C, Papola, D, Passeri, S, Pettorusso, M, Piacenti, S, Pinucci, I, Pugliese, V, Purgato, M, Rania, M, Robbi, F, Romito, S, Ronchi, B, Roselli, V, Segura-Garcia, C, Signorelli, M, Simonelli, G, Sociali, A, Sturiale, S, Tambelli, A, Todesco, B, Trabucco, A, Turrini, G, Villa, V, Wiedenmann, F, Zambuto, L, Zanini, E, Zannini, C, Zerbinati, L, Ostuzzi, Giovanni, Gastaldon, Chiara, Tettamanti, Mauro, Cartabia, Massimo, Monti, Igor, Aguglia, Andrea, Aguglia, Eugenio, Bartoli, Francesco, Callegari, Camilla, Canozzi, Andrea, Carbone, Elvira Anna, Carrà, Giuseppe, Caruso, Rosangela, Cavallotti, Simone, Chiappini, Stefania, Colasante, Fabrizio, Compri, Beatrice, D'Agostino, Armando, De Fazio, Pasquale, de Filippis, Renato, Gari, Matteo, Ielmini, Marta, Ingrosso, Gianmarco, Mammarella, Silvia, Martinotti, Giovanni, Rodolico, Alessandro, Roncone, Rita, Sterzi, Enrico, Tarsitani, Lorenzo, Tiberto, Elisa, Todini, Liliana, Amaddeo, Francesco, D'Avanzo, Barbara, Barbato, Angelo, Barbui, Corrado, Alessi, Maria Chiara, Avincola, Gabriele, Bachi, Bianca, Bernasconi, Gianna, Birgillito, Andrea, Bisso, Emanuele, Bonora, Stefano, Calabrese, Angela, Callovini, Tommaso, Canestro, Aurelia, Canonico, Salvo, Capogrosso, Chiara Alessandra, Carbone, Elvira, Carosielli, Doriana, Caselli, Ivano, Cavaleri, Daniele, Cavallotto, Clara, Cesca, Marco, Chiarenza, Cecilia, Cioni, Riccardo Matteo, Coloccini, Sara, Cruciata, Marco, Cumerlato, Claudia, De Filippis, Renato, De Palma, Manuela, Del Vecchio, Sasha, Della Rocca, Bianca, Di Natale, Chiara, D'Onofrio, Ettore, Espa, Irene, Fior, Giulia, Gancitano, Marta, Giordano, Barbara, Giusti, Laura, Grassi, Luigi, Guzzi, Pierluca, Isella, Celeste, Lax, Annamaria, Marano, Leonardo, Marconi, Federico, Marella, Marco, Metelli, Alessia, Michencig, Giulia, Miuli, Andrea, Moncada, Alessandro, Morello, Pietro, Moretti, Federico, Morreale, Marco, Mosca, Alessio, Nasti, Christian, Nosé, Michela, Ogheri, Filippo, Oresti, Margherita, Ornaghi, Alessandra, Palpella, Dario, Pancheri, Corinna, Papola, Davide, Passeri, Silvia, Pettorusso, Mauro, Piacenti, Susanna, Pinucci, Irene, Pugliese, Valentina, Purgato, Marianna, Rania, Marianna, Robbi, Federica, Romito, Samantha, Ronchi, Barbara, Roselli, Valentina, Segura-Garcia, Cristina, Signorelli, Maria Salvina, Simonelli, Gabriele, Sociali, Antonella, Sturiale, Serena, Tambelli, Antonio, Todesco, Beatrice, Trabucco, Alice, Turrini, Giulia, Villa, Veronica, Wiedenmann, Federico, Zambuto, Luca, Zanini, Elisa, Zannini, Chiara, and Zerbinati, Luigi

Abstract

Background: Major depressive disorder (MDD) is prevalent and disabling among older adults. Standing on its tolerability profile, vortioxetine might be a promising alternative to selective serotonin reuptake inhibitors (SSRIs) in such a vulnerable population. Methods: We conducted a randomised, assessor- and statistician-blinded, superiority trial including older adults with MDD. The study was conducted between 02/02/2019 and 02/22/2023 in 11 Italian Psychiatric Services. Participants were randomised to vortioxetine or one of the SSRIs, selected according to common practice. Treatment discontinuation due to adverse events after six months was the primary outcome, for which we aimed to detect a 12% difference in favour of vortioxetine. The study was registered in the online repository clinicaltrials.gov (NCT03779789). Findings: The intention-to-treat population included 179 individuals randomised to vortioxetine and 178 to SSRIs. Mean age was 73.7 years (standard deviation 6.1), and 264 participants (69%) were female. Of those on vortioxetine, 78 (44%) discontinued the treatment due to adverse events at six months, compared to 59 (33%) of those on SSRIs (odds ratio 1.56; 95% confidence interval 1.01–2.39). Adjusted and per-protocol analyses confirmed point estimates in favour of SSRIs, but without a significant difference. With the exception of the unadjusted survival analysis showing SSRIs to outperform vortioxetine, secondary outcomes provided results consistent with a lack of substantial safety and tolerability differences between the two arms. Overall, no significant differences emerged in terms of response rates, depressive symptoms and quality of life, while SSRIs outperformed vortioxetine in terms of cognitive performance. Interpretation: As opposed to what was previously hypothesised, vortioxetine did not show a better tolerability profile compared to SSRIs in older adults with MDD in this study. Additionally, hypothetical advantages of vortioxetine on depress

Published
2024

3. Longitudinal trajectories of psychosocial functioning in patients with pre-existing mental disorders after one year of COVID-19 pandemic

Author

Luciano, M., primary, Carmassi, C., additional, Sampogna, G., additional, Bertelloni, C.A., additional, Abbate-Daga, G., additional, Albert, U., additional, Castellini, G., additional, Della Rocca, B., additional, Fantasia, S., additional, Menchetti, M., additional, Pedrinelli, V., additional, Pompili, M., additional, Signorelli, M.S., additional, Tosato, S., additional, Massoni e Debora Andreoli, Leonardo, additional, Clesi, Francesca Maria, additional, Bastanzetti, Vittoria, additional, Longo, Paola, additional, Panero, Matteo, additional, Burato, Sofia, additional, D'Aietti, Alberto, additional, Faldi, Marco, additional, Marchesoni, Giorgia, additional, Di Vincenzo, Matteo, additional, Tretola, Lucia, additional, Possidente, Chiara, additional, Cosentini, Nicola, additional, Berardelli, Isabella, additional, Erbuto, Denise, additional, and Fiorillo, A., additional

Published
2024
Full Text
View/download PDF

4. The effect of social media and infodemic on mental health during the COVID-19 pandemic: results from the COMET multicentric trial

Author

Sampogna, G, Di Vincenzo, M, Luciano, M, Della Rocca, B, Albert, U, Carmassi, C, Carra, G, Cirulli, F, Dell'Osso, B, Nanni, M, Pompili, M, Sani, G, Tortorella, A, Volpe, U, Fiorillo, A, Sampogna G., Di Vincenzo M., Luciano M., Della Rocca B., Albert U., Carmassi C., Carra G., Cirulli F., Dell'Osso B., Nanni M. G., Pompili M., Sani G., Tortorella A., Volpe U., Fiorillo A., Sampogna, G, Di Vincenzo, M, Luciano, M, Della Rocca, B, Albert, U, Carmassi, C, Carra, G, Cirulli, F, Dell'Osso, B, Nanni, M, Pompili, M, Sani, G, Tortorella, A, Volpe, U, Fiorillo, A, Sampogna G., Di Vincenzo M., Luciano M., Della Rocca B., Albert U., Carmassi C., Carra G., Cirulli F., Dell'Osso B., Nanni M. G., Pompili M., Sani G., Tortorella A., Volpe U., and Fiorillo A.

Abstract

On January 30, 2020, the World Health Organization (WHO) declared the status of pandemic due to the COVID-19 infection. The initial phases of the pandemic were characterized by uncertainty and public fears. In order to cope with such unexpected conditions, people adopted different coping strategies, including search for information, accessing Internet, and using social media. The present study based on the COMET collaborative research network aims to: (1) assess use of Internet and of social media among the Italian general population; (2) explore differences in web usage between people with pre-existing mental disorders and the general population; (3) identify changes over time in social media usage along the phase 1 of the pandemic; (4) identify the clinical, socio-demographic and contextual predictors of excessive use of social media. A significant increase in time spent on Internet, with an average time of 4.8 ± 0.02 h per day, was found in the global sample of 20,720 participants. Compared with the general population, Internet use was significantly higher in people with pre-existing mental disorders (5.2 ± 0.1 h vs. 4.9 ± 0.02; p < 0.005). According to the multivariate logistic regression model, the risk of excessive use of social media and Internet was significantly higher in people with moderate levels of depressive symptoms (OR: 1.26, CI 95%: 0.99 to 1.59, p < 0.0.005); while protective factors were being students (OR: 0.72, CI 95%: 0.53 to 0.96, p < 0.0029) and living in central Italy (OR: 0.46, CI 95%: 0.23 to 0.90, p < 0.002). The evaluation of social media and Internet use by the general population represents a first step for developing specific protective and supportive interventions for the general population, including practical suggestions on how to safely use Internet and social media.

Published
2023

5. SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor

Author

Romagnoli, A, D'Agostino, M, Pavoni, E, Ardiccioni, C, Motta, S, Crippa, P, Biagetti, G, Notarstefano, V, Rexha, J, Perta, N, Barocci, S, Costabile, B, Colasurdo, G, Caucci, S, Mencarelli, D, Turchetti, C, Farina, M, Pierantoni, L, La Teana, A, Al Hadi, R, Cicconardi, F, Chinappi, M, Trucchi, E, Mancia, F, Menzo, S, Morozzo Della Rocca, B, D'Annessa, I, Di Marino, D, Romagnoli, Alice, D'Agostino, Mattia, Pavoni, Eleonora, Ardiccioni, Chiara, Motta, Stefano, Crippa, Paolo, Biagetti, Giorgio, Notarstefano, Valentina, Rexha, Jesmina, Perta, Nunzio, Barocci, Simone, Costabile, Brianna K, Colasurdo, Gabriele, Caucci, Sara, Mencarelli, Davide, Turchetti, Claudio, Farina, Marco, Pierantoni, Luca, La Teana, Anna, Al Hadi, Richard, Cicconardi, Francesco, Chinappi, Mauro, Trucchi, Emiliano, Mancia, Filippo, Menzo, Stefano, Morozzo Della Rocca, Blasco, D'Annessa, Ilda, Di Marino, Daniele, Romagnoli, A, D'Agostino, M, Pavoni, E, Ardiccioni, C, Motta, S, Crippa, P, Biagetti, G, Notarstefano, V, Rexha, J, Perta, N, Barocci, S, Costabile, B, Colasurdo, G, Caucci, S, Mencarelli, D, Turchetti, C, Farina, M, Pierantoni, L, La Teana, A, Al Hadi, R, Cicconardi, F, Chinappi, M, Trucchi, E, Mancia, F, Menzo, S, Morozzo Della Rocca, B, D'Annessa, I, Di Marino, D, Romagnoli, Alice, D'Agostino, Mattia, Pavoni, Eleonora, Ardiccioni, Chiara, Motta, Stefano, Crippa, Paolo, Biagetti, Giorgio, Notarstefano, Valentina, Rexha, Jesmina, Perta, Nunzio, Barocci, Simone, Costabile, Brianna K, Colasurdo, Gabriele, Caucci, Sara, Mencarelli, Davide, Turchetti, Claudio, Farina, Marco, Pierantoni, Luca, La Teana, Anna, Al Hadi, Richard, Cicconardi, Francesco, Chinappi, Mauro, Trucchi, Emiliano, Mancia, Filippo, Menzo, Stefano, Morozzo Della Rocca, Blasco, D'Annessa, Ilda, and Di Marino, Daniele

Abstract

Reliable point-of-care (POC) rapid tests are crucial to detect infection and contain the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The emergence of several variants of concern (VOC) can reduce binding affinity to diagnostic antibodies, limiting the efficacy of the currently adopted tests, while showing unaltered or increased affinity for the host receptor, angiotensin converting enzyme 2 (ACE2). We present a graphene field-effect transistor (gFET) biosensor design, which exploits the Spike-ACE2 interaction, the crucial step for SARS-CoV-2 infection. Extensive computational analyses show that a chimeric ACE2-Fragment crystallizable (ACE2-Fc) construct mimics the native receptor dimeric conformation. ACE2-Fc functionalized gFET allows in vitro detection of the trimeric Spike protein, outperforming functionalization with a diagnostic antibody or with the soluble ACE2 portion, resulting in a sensitivity of 20 pg/mL. Our miniaturized POC biosensor successfully detects B.1.610 (pre-VOC), Alpha, Beta, Gamma, Delta, Omicron (i.e., BA.1, BA.2, BA.4, BA.5, BA.2.75 and BQ.1) variants in isolated viruses and patient's clinical nasopharyngeal swabs. The biosensor reached a Limit Of Detection (LOD) of 65 cps/mL in swab specimens of Omicron BA.5. Our approach paves the way for a new and reusable class of highly sensitive, rapid and variant-robust SARS-CoV-2 detection systems.

Published
2023

6. Effect of affective temperament on illness characteristics of subjects with bipolar disorder and major depressive disorder

Author

Simonetti, Alessio, Luciano, Rita Paola Maria, Sampogna, G., Della Rocca, B., Mancuso, Enrico Maria, De Fazio, P., Di Nicola, Marco, Di Lorenzo, G., Pepe, Maria, Sambataro, F., Signorelli, M. S., Koukopoulos, A. E., Chiaie, R. D., Fiorillo, A., Sani, Gabriele, Simonetti A., Luciano M. (ORCID:0000-0003-4358-0757), Mancuso E. (ORCID:0000-0002-8519-4945), Di Nicola M. (ORCID:0000-0001-7457-0426), Pepe M., Sani G. (ORCID:0000-0002-9767-8752), Simonetti, Alessio, Luciano, Rita Paola Maria, Sampogna, G., Della Rocca, B., Mancuso, Enrico Maria, De Fazio, P., Di Nicola, Marco, Di Lorenzo, G., Pepe, Maria, Sambataro, F., Signorelli, M. S., Koukopoulos, A. E., Chiaie, R. D., Fiorillo, A., Sani, Gabriele, Simonetti A., Luciano M. (ORCID:0000-0003-4358-0757), Mancuso E. (ORCID:0000-0002-8519-4945), Di Nicola M. (ORCID:0000-0001-7457-0426), Pepe M., and Sani G. (ORCID:0000-0002-9767-8752)

Abstract

Background: Affective temperaments represent the stable, biologically determined substrates of mood disorders. The relationship between affective temperaments and bipolar disorder (BD) or major depressive disorder (MDD) has been described. However, the strength of such relationship should be tested while considering other factors influencing the diagnosis of BD/MDD. Literature also lacks a comprehensive description of the interplay between affective temperament and characteristics of mood disorders. The aim of the present study is to address these issues. Methods: This is a multicentric observational study including 7 Italian university sites. Five-hundred-fifty-five euthymic subjects with BD/MDD were enrolled and further divided in those with hyperthymic (Hyper, N = 143), cyclothymic (Cyclo, N = 133), irritable (Irr, N = 49), dysthymic (Dysth, N = 155), and anxious (Anx N = 76) temperaments. Linear, binary, ordinal and logistic regressions were performed to assess the association between affective temperaments and i) diagnosis of BD/MDD; ii) characteristics of illness severity and course. Results: Hyper, Cyclo and Irr were more likely to be associated with BD, together with earlier age of onset and presence of a first-degree relative with BD. Anx and Dysth were more associated with MDD. Differences in association between affective temperaments and characteristics of BD/MDD were observed for hospital admissions, phase-related psychotic symptoms, length and type of depression, comorbidity and pharmacological intake. Limitations: Small sample size, cross-sectional design, recall biases. Conclusion: Specific affective temperaments were associated to certain characteristics of illness severity and course of BD or MDD. Evaluation of affective temperaments might help a deeper understanding of mood disorders.

Published
2023

8. Effect of affective temperament on illness characteristics of subjects with bipolar disorder and major depressive disorder

Author

Simonetti, A., Luciano, M., Sampogna, G., Rocca, B. D., Mancuso, E., De Fazio, P., Di Nicola, M., Di Lorenzo, G., Pepe, M., Sambataro, F., Signorelli, M. S., Koukopoulos, A. E., Chiaie, R. D., Fiorillo, A., Sani, G., Simonetti, Alessio, Luciano, Mario, Sampogna, Gaia, Rocca, Bianca Della, Mancuso, Emiliana, De Fazio, Pasquale, Di Nicola, Marco, Di Lorenzo, Giorgio, Pepe, Maria, Sambataro, Fabio, Signorelli, Maria Salvina, Koukopoulos, Alexia Emilia, Chiaie, Roberto Delle, Fiorillo, Andrea, and Sani, Gabriele

Subjects
Psychiatry and Mental health, Clinical Psychology, Bipolar disorder, Diagnosis, Course, Temperament, Major affective disorder, Diagnosi
Abstract

Background: Affective temperaments represent the stable, biologically determined substrates of mood disorders. The relationship between affective temperaments and bipolar disorder (BD) or major depressive disorder (MDD) has been described. However, the strength of such relationship should be tested while considering other factors influencing the diagnosis of BD/MDD. Literature also lacks a comprehensive description of the interplay between affective temperament and characteristics of mood disorders. The aim of the present study is to address these issues. Methods: This is a multicentric observational study including 7 Italian university sites. Five-hundred-fifty-five euthymic subjects with BD/MDD were enrolled and further divided in those with hyperthymic (Hyper, N=143), cyclothymic (Cyclo, N=133), irritable (Irr, N=49), dysthymic (Dysth, N=155), and anxious (Anx N=76) temperaments. Linear, binary, ordinal and logistic regressions were performed to assess the association between affective temperaments and i) diagnosis of BD/MDD; ii) characteristics of illness severity and course. Results: Hyper, Cyclo and Irr were more likely to be associated with BD, together with earlier age of onset and presence of a first-degree relative with BD. Anx and Dysth were more associated with MDD. Differences in association between affective temperaments and characteristics of BD/MDD were observed for hospital admissions, phase-related psychotic symptoms, length and type of depression, comorbidity and pharmacological intake. Limitations: Small sample size, cross-sectional design, recall biases. Conclusion: Specific affective temperaments were associated to certain characteristics of illness severity and course of BD or MDD. Evaluation of affective temperaments might help a deeper understanding of mood disorders.

Published
2023

10. Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease

Author

Petrucci, G, primary, Viti, L, additional, Sacco, M, additional, Hatem, D, additional, Lancellotti, S, additional, Rizzi, A, additional, Zaccardi, F, additional, De Cristofaro, R, additional, Pitocco, D, additional, Patrono, C, additional, and Rocca, B, additional

Published
2022
Full Text
View/download PDF

20. Physical activity and treatment adherence in patients with mental disorders: a randomized controlled trial.

Author

Silvestro, R., Dello Stritto, V., Catapano, P., Di Vincenzo, M., Della Rocca, B., Lapadula, M. V., Toni, C., Bello, R., Luciano, M., Sampogna, G., and Fiorillo, A.

Subjects
PATIENT compliance, PHYSICAL activity, RANDOMIZED controlled trials, QUALITY of life, FUNCTIONAL status
Abstract

Introduction: Lack of adherence to pharmacological treatment is considered a multifactorial phenomenon, remarkably frequent in clinical practice. Non-adherence is associated with increased number of relapses, poor clinical and functional outcomes, and worsening of patient health status, with a resulting increase in healthcare costs, particularly in people with severe mental disorders (SMD). Treatment adherence rates remain extremely low, highlighting the need to develop innovative and integrated strategies; one of these is represented by the promotion of healthy lifestyle behaviours, including regular physical activity. Objectives: The aim of this study is to assess how the rates of treatment adherence vary in patients with SMD after receiving a psychosocial intervention, focusing on the positive relationship between treatment adherence and physical activity. Methods: LIFESTYLE is a randomized controlled trial comparing the efficacy of a structured psychosocial lifestyle intervention involving moderate physical activity exercises over a brief psychoeducational intervention. Levels of physical activity was assessed thorough the IPAQ scale, while treatment adherence was evaluated by the Morisky Medication Adherence Scale (MMAS). Results: The sample includes 401 patients, with a mean duration of illness was 16.3 (±17.8) years. All patients were receiving a pharmacological drug treatment; in particular, 59.6% (N=239) were treated with a second-generation antipsychotic and 54.9% (N=220) with a mood stabilizer. Our results show that moderate physical activity improves rates of treatment adherence. After 6 months, adherence to treatment increased from 35.8% at baseline to 47.6% at baseline in the experimental group, along with improvement in clinical health parameters (reduction in BMI, weight, and metabolic parameters). Another significant inverse correlation was found between adherence and quality of life (Rho di Person: -.140, p<.005). Furthermore, this study indicates that having a diagnosis of major depression, a better cognitive functioning, a shorter duration of illness and contact time with the local mental health centre are factors that positively influence treatment adherence. Remarkably, treatment adherence was not influenced by symptom severity and type of pharmacological treatment. Conclusions: Moderate physical activity can represent a valid strategy to increase treatment adherence in patients with SMD. Therefore, promoting physical activity exercises in our clinical practice may be associated with better outcomes. However, further studies that evaluate patients with acute mental disorders are needed. Disclosure of Interest: None Declared [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. The improvement of mental and physical health of people with severe mental disorder: one-year efficacy of a lifestyle experimental intervention.

Author

Carbone, M., Mario, L., Di Vincenzo, M., Della Rocca, B., Toni, C., Cipolla, S., Martinelli, F., Sampogna, G., and Fiorillo, A.

Subjects
PSYCHOPHARMACOLOGY, MENTAL illness, PSYCHOSES, CONTROL (Psychology), MENTAL depression
Abstract

Introduction: Patients with severe mental disorders have a significantly reduced life expectancy than the general population, often resulting from the increased prevalence of cardiovascular and metabolic diseases. Reasons include unhealthy lifestyle behaviours, reduced access to screening programs and adverse effects of many psychotropic drugs. Objectives: Our goal is to assess the efficacy of a psychosocial group intervention promoting healthy lifestyle behaviors compared to a brief psychoeducational group intervention in terms of improvement of severity of psychiatric symptoms and perceived quality of life, and a series of anthropometric and hematological parameters. Methods: This is a multicenter randomized controlled trial. Patients between 18 and 35 years of age with a diagnosis of schizophrenia and other primary psychotic disorders, unipolar depression and bipolar disorder were recruited. Exclusion criteria were inability to perform moderate physical activity, pregnancy and breastfeeding and impaired cognitive functions. Results: 401 patients were recruited and randomly assigned to receive the experimental intervention (LIFESTYLE) or a behavioural control intervention. About 57% of the sample were female, with a mean age of 45.8±11.8, and BMI of 32.5±5.5. All of them were receiving almost one psychotropic drug. At one year, we observed a reduction in HOMA-IR index (from 4.3 ± 5.5 to 3.1 ± 2.9, p<0.01) and triglycerides (from 162.5 ± 78.1 mg/dL to 131.4 ± 76.0 mg/dL, p<0.001), as well as an increase in HDL (from 46.2± 14.6 mg/dL to 50.9±26.7 mg/dL, p<0.05). Moreover, a reduction in the values of BPRS "Affectivity" (from 8.7±3.0 to 7.2±2.5, p<0.001), "Activity" (from 4.7±1.9 to 4.2±1.3, p<0.01) and "Negative Symptoms" subscale (from 7.7±3.1 to 7.0±2.7, p<0.001) was also observed, along with an improvement in perceived quality of life (MANSA total score from 4.0 ± 1.0 to 5.3 ± 0.8, p<0.01). Conclusions: The results support the evidence that the LIFESTYLE intervention has long-lasting positive effects on physical and mental health of people with mental disorders. More efforts need to be done in order to increase the availability of these treatments in routine clinical settings. Disclosure of Interest: None Declared [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation

Author

Petrucci, G, Zaccardi, F, Giaretta, A, Cavalca, V, Capristo, E, Cardillo, C, Pitocco, D, Porro, B, Schinzari, F, Toffolo, G, Tremoli, E, Rocca, B, Petrucci G (ORCID:0000-0002-9280-3673), Capristo E (ORCID:0000-0002-5753-3495), Pitocco D (ORCID:0000-0002-6220-686X), Schinzari F, Tremoli E, Rocca B (ORCID:0000-0001-8304-6423), Petrucci, G, Zaccardi, F, Giaretta, A, Cavalca, V, Capristo, E, Cardillo, C, Pitocco, D, Porro, B, Schinzari, F, Toffolo, G, Tremoli, E, Rocca, B, Petrucci G (ORCID:0000-0002-9280-3673), Capristo E (ORCID:0000-0002-5753-3495), Pitocco D (ORCID:0000-0002-6220-686X), Schinzari F, Tremoli E, and Rocca B (ORCID:0000-0001-8304-6423)

Abstract

Background: The prevalence and degree of obesity is rising worldwide, increases cardiovascular risk, modifies body composition and organ function, and potentially affects the pharmacokinetics and/or pharmacodynamics of drugs. Objectives: To investigate the pharmacodynamics of once-daily low-dose aspirin in healthy obese subjects, and to assess whether body weight (BW) and body mass index (BMI) affect the pharmacology of aspirin. Patients/methods: Otherwise healthy, obese (BMI > 30 kg/m2 ) subjects were studied before and after 3-4 weeks of 100-mg once-daily aspirin intake. Aspirin pharmacodynamics were assessed according to serum thromboxane (TX) B2 levels measured at 4 hours, 24 hours (i.e., posologic interval) and 48 hours after the last witnessed intake; age-matched and sex-matched non-obese controls were included. A previously calibrated pharmacokinetic/pharmacodynamic in silico model of aspirin was used to fit serum TXB2 data from obese subjects. At baseline, the major urinary TXA2 and prostacyclin metabolites, urinary isoprostane and plasma inflammatory biomarkers were measured. Results: In 16 obese subjects (aged 47 ± 11 years; BMI of 39.4 ± 5.1 kg/m2 ), residual serum TXB2 values between 4 and 48 hours after aspirin intake were increased 3- to 5-fold as compared with controls. At 24 hours, the residual serum TXB2 level was log-linearly associated with body size over a wide range of BMI and BW values, without any apparent threshold. The in silico model predicted that reduced aspirin bioavailability would be inversely related to body size and rescued by 200 mg of aspirin once daily or 85 mg twice daily. Baseline urinary TXA2 metabolite, isoprostane and plasma C-reactive protein levels were significantly increased in obese subjects. Conclusions: Obesity is associated with impaired aspirin responsiveness, largely because of body size. Impaired inhibition of platelet activation by conventional low-dose aspirin may affect antithrombotic efficacy.

Published
2019

25. Antithrombotic therapy in diabetes: which, when, and for how long?

Author

Ajjan, R.A., Kietsiriroje, N., Badimon, L., Vilahur, G., Gorog, D.A., Angiolillo, D.J., Russell, D.A., Rocca, B., and Storey, R.F.

Abstract

Cardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbidity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced thrombotic environment, contributes to the high vascular risk in individuals with DM. This prothrombotic milieu is due to increased platelet activity together with impaired fibrinolysis secondary to quantitative and qualitative changes in coagulation factors. However, management strategies to reduce thrombosis risk remain largely similar in individuals with and without DM. The current review covers the latest in the field of antithrombotic management in DM. The role of primary vascular prevention is discussed together with options for secondary prevention following an ischaemic event in different clinical scenarios including coronary, cerebrovascular, and peripheral artery diseases. Antiplatelet therapy combinations as well as combination of antiplatelet and anticoagulant agents are examined in both the acute phase and long term, including management of individuals with sinus rhythm and those with atrial fibrillation. The difficulties in tailoring therapy according to the variable atherothrombotic risk in different individuals are emphasized, in addition to the varying risk within an individual secondary to DM duration, presence of complications and predisposition to bleeding events. This review provides the reader with an up-to-date guide for antithrombotic management of individuals with DM and highlights gaps in knowledge that represent areas for future research, aiming to improve clinical outcome in this high-risk population.

Published
2021

29. Aspirin at 120: Retiring, recombining, or repurposing?

Author

Patrono, Carlo, Rocca, Bianca, Patrono C., Rocca B. (ORCID:0000-0001-8304-6423), Patrono, Carlo, Rocca, Bianca, Patrono C., and Rocca B. (ORCID:0000-0001-8304-6423)

Abstract

During the past 20 years, we have witnessed the following trends in aspirin usage: (i) a “dropping” trend, characterized by the early discontinuation of low-dose aspirin from dual antiplatelet therapy or triple antithrombotic therapy (oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation) following an acute coronary syndrome or after percutaneous coronary intervention; (ii) a “combinatorial” trend, featuring the addition of a lower dose of a P2Y12 inhibitor or direct oral anticoagulant drug to low-dose aspirin for the long-term treatment of stable patients with atherosclerotic cardiovascular disease; and (iii) a “repurposing” trend, characterized by growing interest in the oncologic community to assess the chemopreventive effect of aspirin against certain types of cancers (particularly of the gastrointestinal tract), both as primary prevention and adjuvant therapy. The aim of this review is to present the mechanistic rationale underlying these trends, discuss the design and findings of trials testing novel treatments or new therapeutic applications of aspirin, and report on the ISTH Congress results on this topic.

Published
2021

30. How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group

Author

Rubboli, A., Fresco, C., Paciaroni, M., Rocca, Bianca, Pecora, D., Enea, I., Cuccia, C., Patti, G., Rocca B. (ORCID:0000-0001-8304-6423), Rubboli, A., Fresco, C., Paciaroni, M., Rocca, Bianca, Pecora, D., Enea, I., Cuccia, C., Patti, G., and Rocca B. (ORCID:0000-0001-8304-6423)

Abstract

AIM: To evaluate the current interpretation of the lower doses of direct oral anticoagulants (DOAC) dabigatran, apixaban, edoxaban and rivaroxaban in nonvalvular atrial fibrillation. METHODS: A questionnaire of 14 statements to which the possible answers were fully agree/partially agree/partially disagree/fully disagree or yes/no was prepared within the board of the Italian Atherosclerosis, Thrombosis and Vascular Biology Study Group and forwarded to individual Italian physicians. RESULTS: A total of 620 complete questionnaires were received from nearly all the Italian regions and physicians of various medical specialists, either enabled or not for the prescription of DOAC. A wide agreement was found as regards the pharmacological, as well as clinical consequences of the administration of the lower dose of factor-Xa inhibitors both in patients with and without clinical and/or laboratory criteria requiring dose reduction. Wide agreement was also found as regards the presence of moderate kidney insufficiency in selecting the dose of DOAC. Instead, more debated were issues regarding the proportionality between dabigatran dose and plasma concentration and selection of dabigatran dose, as well as the role of measuring drug plasma concentration and/or determine the anticoagulant activity of factor-Xa inhibitors when used at the lower dose. CONCLUSION: The interpretation of the lower doses of DOAC in current Italian clinical practice appears largely correct and shared. Because of the persistence of some residual uncertainties, essentially regarding dabigatran, however, continuous educational effort still appears warranted.

Published
2021

31. Prevention Italy 2021 - An update of the 2018 Consensus document and recommendations for the prevention of cardiovascular disease in Italy [Prevenzione Italia 2021 Un update del Documento di consenso e raccomandazioni per la prevenzione cardiovascolare in Italia]

Author

Battistoni, A, Gallo, G, Aragona, C, Barchiesi, F, Basolo, A, Bellone, S, Bellotti, P, Bertolotti, M, Bianco, A, Biffi, A, Borghi, C, Cicero, A, Consoli, A, Corsini, A, Desideri, G, Di Giacinto, B, Fernando, F, Ferri, C, Galiuto, L, Grassi, D, Grassi, G, Icardi, G, Indolfi, C, Lodi, E, Modena, M, Muiesan, M, Nati, G, Orsi, A, Palermi, S, Parati, G, Passantino, A, Patelli, A, Pelliccia, A, Pengo, M, Filardi, P, Perseghin, G, Pirro, M, Pontremoli, R, Rengo, G, Ricotti, R, Rizzoni, D, Rocca, B, Rotella, C, Rubattu, S, Salvetti, G, Sciacqua, A, Serdoz, A, Sirico, F, Squeo, M, Tocci, G, Trimarco, B, Vigili de Kreutzenberg, S, Volpe, R, Volpe, M, Battistoni, Allegra, Gallo, Giovanna, Aragona, Caterina Oriana, Barchiesi, Fabio, Basolo, Alessio, Bellone, Simonetta, Bellotti, Paolo, Bertolotti, Marco, Bianco, Andrea, Biffi, Alessandro, Borghi, Claudio, Cicero, Arrigo Francesco Giuseppe, Consoli, Agostino, Corsini, Alberto, Desideri, Giovambattista, Di Giacinto, Barbara, Fernando, Fredrik, Ferri, Claudio, Galiuto, Leonarda, Grassi, Davide, Grassi, Guido, Icardi, Giancarlo, Indolfi, Ciro, Lodi, Elisa, Modena, Maria Grazia, Muiesan, Maria Lorenza, Nati, Giulio, Orsi, Andrea, Palermi, Stefano, Parati, Gianfranco, Passantino, Andrea, Patelli, Alessandra, Pelliccia, Antonio, Pengo, Martino, Filardi, Pasquale Perrone, Perseghin, Gianluca, Pirro, Matteo, Pontremoli, Roberto, Rengo, Giuseppe, Ricotti, Roberta, Rizzoni, Damiano, Rocca, Bianca, Rotella, Carlo, Rubattu, Speranza, Salvetti, Guido, Sciacqua, Angela, Serdoz, Andrea, Sirico, Felice, Squeo, Maria Rosaria, Tocci, Giuliano, Trimarco, Bruno, Vigili de Kreutzenberg, Saula, Volpe, Roberto, Volpe, Massimo, Battistoni, A, Gallo, G, Aragona, C, Barchiesi, F, Basolo, A, Bellone, S, Bellotti, P, Bertolotti, M, Bianco, A, Biffi, A, Borghi, C, Cicero, A, Consoli, A, Corsini, A, Desideri, G, Di Giacinto, B, Fernando, F, Ferri, C, Galiuto, L, Grassi, D, Grassi, G, Icardi, G, Indolfi, C, Lodi, E, Modena, M, Muiesan, M, Nati, G, Orsi, A, Palermi, S, Parati, G, Passantino, A, Patelli, A, Pelliccia, A, Pengo, M, Filardi, P, Perseghin, G, Pirro, M, Pontremoli, R, Rengo, G, Ricotti, R, Rizzoni, D, Rocca, B, Rotella, C, Rubattu, S, Salvetti, G, Sciacqua, A, Serdoz, A, Sirico, F, Squeo, M, Tocci, G, Trimarco, B, Vigili de Kreutzenberg, S, Volpe, R, Volpe, M, Battistoni, Allegra, Gallo, Giovanna, Aragona, Caterina Oriana, Barchiesi, Fabio, Basolo, Alessio, Bellone, Simonetta, Bellotti, Paolo, Bertolotti, Marco, Bianco, Andrea, Biffi, Alessandro, Borghi, Claudio, Cicero, Arrigo Francesco Giuseppe, Consoli, Agostino, Corsini, Alberto, Desideri, Giovambattista, Di Giacinto, Barbara, Fernando, Fredrik, Ferri, Claudio, Galiuto, Leonarda, Grassi, Davide, Grassi, Guido, Icardi, Giancarlo, Indolfi, Ciro, Lodi, Elisa, Modena, Maria Grazia, Muiesan, Maria Lorenza, Nati, Giulio, Orsi, Andrea, Palermi, Stefano, Parati, Gianfranco, Passantino, Andrea, Patelli, Alessandra, Pelliccia, Antonio, Pengo, Martino, Filardi, Pasquale Perrone, Perseghin, Gianluca, Pirro, Matteo, Pontremoli, Roberto, Rengo, Giuseppe, Ricotti, Roberta, Rizzoni, Damiano, Rocca, Bianca, Rotella, Carlo, Rubattu, Speranza, Salvetti, Guido, Sciacqua, Angela, Serdoz, Andrea, Sirico, Felice, Squeo, Maria Rosaria, Tocci, Giuliano, Trimarco, Bruno, Vigili de Kreutzenberg, Saula, Volpe, Roberto, and Volpe, Massimo

Published
2021

32. Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease

Author

Parker, W. A. E., Gorog, D. A., Geisler, T., Vilahur, G., Sibbing, D., Rocca, Bianca, Storey, R. F., Rocca B. (ORCID:0000-0001-8304-6423), Parker, W. A. E., Gorog, D. A., Geisler, T., Vilahur, G., Sibbing, D., Rocca, Bianca, Storey, R. F., and Rocca B. (ORCID:0000-0001-8304-6423)

Abstract

Stroke is a common and devastating condition caused by atherothrombosis, thromboembolism, or haemorrhage. Patients with chronic coronary syndromes (CCS) or peripheral artery disease (PAD) are at increased risk of stroke because of shared pathophysiological mechanisms and risk-factor profiles. A range of pharmacological and non-pharmacological strategies can help to reduce stroke risk in these groups. Antithrombotic therapy reduces the risk of major adverse cardiovascular events, including ischaemic stroke, but increases the incidence of haemorrhagic stroke. Nevertheless, the net clinical benefits mean antithrombotic therapy is recommended in those with CCS or symptomatic PAD. Whilst single antiplatelet therapy is recommended as chronic treatment, dual antiplatelet therapy should be considered for those with CCS with prior myocardial infarction at high ischaemic but low bleeding risk. Similarly, dual antithrombotic therapy with aspirin and very-low-dose rivaroxaban is an alternative in CCS, as well as in symptomatic PAD. Full-dose anticoagulation should always be considered in those with CCS/PAD and atrial fibrillation. Unless ischaemic risk is particularly high, antiplatelet therapy should not generally be added to full-dose anticoagulation. Optimization of blood pressure, low-density lipoprotein levels, glycaemic control, and lifestyle characteristics may also reduce stroke risk. Overall, a multifaceted approach is essential to best prevent stroke in patients with CCS/PAD.

Published
2021

34. Prevention Italy 2021 - An update of the 2018 Consensus document and recommendations for the prevention of cardiovascular disease in Italy

Author

Battistoni, A., Gallo, G., Aragona, C. O., Barchiesi, F., Basolo, A., Bellone, S., Bellotti, P., Bertolotti, M., Bianco, A., Biffi, A., Borghi, C., Cicero, A. F. G., Consoli, A., Corsini, A., Desideri, G., Di Giacinto, B., Fernando, F., Ferri, C., Galiuto, L., Grassi, D., Grassi, G., Icardi, G., Indolfi, C., Lodi, E., Modena, M. G., Muiesan, M. L., Nati, G., Orsi, A., Palermi, S., Parati, G., Passantino, A., Patelli, A., Pelliccia, A., Pengo, M., Filardi, P. P., Perseghin, G., Pirro, M., Pontremoli, R., Rengo, G., Ricotti, R., Rizzoni, D., Rocca, B., Rotella, C., Rubattu, S., Salvetti, G., Sciacqua, A., Serdoz, A., Sirico, F., Squeo, M. R., Tocci, G., Trimarco, B., Vigili de Kreutzenberg, S., Volpe, R., and Volpe, M.

Subjects
Consensus, Italy, Humans, Risk Assessment, Risk Factors, Cardiovascular Diseases
Published
2021

35. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis

Author

Badimon, L, Vilahur, G, Rocca, B, and Patrono, C

Subjects
Platelets, Arachidonic acid, Aspirin, Eicosanoids, lipids (amino acids, peptides, and proteins), Thrombosis, Non-steroidal anti-inflammatory drugs, Haemostasis
Abstract

Arachidonic acid is one of the most abundant and ubiquitous omega-6 polyunsaturated fatty acid, present in esterified form in the membrane phospholipids of all mammalian cells and released from phospholipids by several phospholipases in response to various activating or inhibitory stimuli. Arachidonic acid is the precursor of a large number of enzymatically and non-enzymatically derived, biologically active autacoids, including prostaglandins (PGs), thromboxane (TX) A(2), leukotrienes, and epoxyeicosatetraenoic acids (collectively called eicosanoids), endocannabinoids and isoprostanes, respectively. Eicosanoids are local modulators of the physiological functions and pathophysiological rotes of blood vessels and platelets. For example, the importance of cyctooxygenase (COX)-1-derived TXA(2) from activated platelets in contributing to primary haemostasis and atherothrombosis is demonstrated in animal and human models by the bleeding complications and cardioprotective effects associated with low-dose aspirin, a selective inhibitor of platelet COX-1. The relevance of vascular COX-2-derived prostacyclin (PGI(2)) in endothelial thromboresistance and atheroprotection is clearly shown by animal and human models and by the adverse cardiovascular effects exerted by COX-2 inhibitors in humans. A vast array of arachidonic acid-transforming enzymes, downstream synthases and isomerases, transmembrane receptors, and specificity in their tissue expression make arachidonic acid metabolism a fine-tuning system of vascular health and disease. Its pharmacological regulation is central in human cardiovascular diseases, as demonstrated by biochemical measurements and intervention trials.

Published
2021

39. Clinical Practice Guides ESC 2019 guide on diabetes, prediabetes and cardiovascular disease, in collaboration with the European Association for the Study of Diabetes (EASD)

Author

Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D.E., Hansen, T.B., Huikuri, H.V., Johansson, I., Juni, P., Lettino, M., Marx, N., Mellbin, L.G., Ostgren, C.J., Rocca, B., Roffi, M., Sattar, N., Seferovic, P.M., Sousa-Uva, M., Valensi, P., Wheeler, D.C., Grp Trabajo Diabet Prediabet Enfer, and European Assoc Study Diabet EASD

Published
2020

41. Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: Benefits and risks of antithrombotic therapy for cardiovascular disease prevention

Author

Walker, J., Cattaneo, M., Badimon, L., Agnelli, G., Chan, A.T., Lanas, A., Rocca, B., Rothwell, P., Patrignani, P., Langley, R., Vilahur, G., and Cosentino, F.

Subjects
Cancer Research, Settore BIO/14 - FARMACOLOGIA, aspirin, cardiovascular disease (CVD), benefit, precision medicine, anticoagulant, primary prevention, Conference Report, antithrombotic, antiplatelet, colorectal cancer (CRC), optimizing aspirin dose, secondary prevention, risk, upper gastrointestinal (GI) bleeding, gastroprotectant agents, targeting, diabetes mellitus (DM), Oncology
Abstract

At the 2019 International Aspirin Foundation Scientific Conference ‘Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.

Published
2020

42. In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance

Author

Santilli, F, Zaccardi, F, Liani, R, Petrucci, Giovanna, Simeone, P, Pitocco, Dario, Tripaldi, R, Rizzi, A, Formoso, G, Pontecorvi, Alfredo, Angelucci, E, Pagliaccia, F, Golato, M, De Leva, Francesca, Vitacolonna, E, Rocca, Bianca, Consoli, A, Patrono, Carlo, Petrucci G (ORCID:0000-0002-9280-3673), Pitocco D (ORCID:0000-0002-6220-686X), Pontecorvi A (ORCID:0000-0003-0570-6865), De Leva F, Rocca B (ORCID:0000-0001-8304-6423), Patrono C, Santilli, F, Zaccardi, F, Liani, R, Petrucci, Giovanna, Simeone, P, Pitocco, Dario, Tripaldi, R, Rizzi, A, Formoso, G, Pontecorvi, Alfredo, Angelucci, E, Pagliaccia, F, Golato, M, De Leva, Francesca, Vitacolonna, E, Rocca, Bianca, Consoli, A, Patrono, Carlo, Petrucci G (ORCID:0000-0002-9280-3673), Pitocco D (ORCID:0000-0002-6220-686X), Pontecorvi A (ORCID:0000-0003-0570-6865), De Leva F, Rocca B (ORCID:0000-0001-8304-6423), and Patrono C

Abstract

Background: Impaired glucose tolerance (IGT) is associated with increased cardiovascular morbidity and mortality. Enhanced thromboxane (TX)-dependent platelet activation plays a pivotal role in atherothrombosis and characterizes type 2 diabetes mellitus (DM). Whether this also pertains to IGT is currently unknown. We investigated whether TXA2 -dependent platelet activation, as reflected by 11-dehydro-TXB2 (TXM) urinary excretion, is comparably abnormal in IGT as in DM, is persistent over long-term follow-up, changes as a function of metabolic disease progression, and is influenced by food intake. Methods: We prospectively investigated subjects with IGT (n = 48) and two control groups with DM diagnosed either less than 12 months (n = 60) or 12 months or more (n = 58). Results: Baseline TXM excretion was comparable between subjects with IGT and DM, with no evidence of a circadian variation. During a 36-month follow-up, urinary TXM excretion was stable over time in the DM groups, while tended to increase in subjects with IGT. Increasing urinary TXM excretion over time was observed in the subjects who progressed to diabetes vs nonprogressors. Conclusions: We conclude that TXA2 -dependent platelet activation was at least as high in IGT as in patients with DM and further increased over time, especially in those who progressed to overt diabetes.

Published
2020

43. Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial

Author

Drew, D. A., Schuck, M. M., Magicheva-Gupta, M. V., Stewart, K. O., Gilpin, K. K., Miller, P., Parziale, M. P., Pond, E. N., Takacsi-Nagy, O., Zerjav, D. C., Chin, S. M., Krems, J. M., Meixell, D., Joshi, A. D., Ma, W., Colizzo, F. P., Carolan, P. J., Nishioka, N. S., Staller, K., Richter, J. M., Khalili, H., Gala, M. K., Garber, J. J., Chung, D. C., Yarze, J. C., Zukerberg, L., Petrucci, Giovanna, Rocca, Bianca, Patrono, Carlo, Milne, G. L., Wang, M., Chan, A. T., Petrucci G. (ORCID:0000-0002-9280-3673), Rocca B. (ORCID:0000-0001-8304-6423), Patrono C., Drew, D. A., Schuck, M. M., Magicheva-Gupta, M. V., Stewart, K. O., Gilpin, K. K., Miller, P., Parziale, M. P., Pond, E. N., Takacsi-Nagy, O., Zerjav, D. C., Chin, S. M., Krems, J. M., Meixell, D., Joshi, A. D., Ma, W., Colizzo, F. P., Carolan, P. J., Nishioka, N. S., Staller, K., Richter, J. M., Khalili, H., Gala, M. K., Garber, J. J., Chung, D. C., Yarze, J. C., Zukerberg, L., Petrucci, Giovanna, Rocca, Bianca, Patrono, Carlo, Milne, G. L., Wang, M., Chan, A. T., Petrucci G. (ORCID:0000-0002-9280-3673), Rocca B. (ORCID:0000-0001-8304-6423), and Patrono C.

Abstract

Low-dose aspirin is recommended by the U.S. Preventive Services Task Force for primary prevention of colorectal cancer in certain individuals. However, broader implementation will require improved precision prevention approaches to identify those most likely to benefit. The major urinary metabolite of PGE2, 11a-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), is a biomarker for colorectal cancer risk, but it is unknown whether PGE-M is modifiable by aspirin in individuals at risk for colorectal cancer. Adults (N 1⁄4 180) who recently underwent adenoma resection and did not regularly use aspirin or NSAIDs were recruited to a double-blind, placebo-controlled, randomized trial of aspirin at 81 or 325 mg/day for 8–12 weeks. The primary outcome was postintervention change in urinary PGE-M as measured by LC/MS. A total of 169 participants provided paired urine samples for analysis. Baseline PGE-M excretion was 15.9 = 14.6 (mean = S.D, ng/mg creatinine). Aspirin significantly reduced PGE-M excretion (=4.7 = 14.8) compared with no decrease (0.8 = 11.8) in the placebo group (P 1⁄4 0.015; mean duration of treatment 1⁄4 68.9 days). Aspirin significantly reduced PGE-M levels in participants receiving either 81 (-15%; P 1⁄4 0.018) or 325 mg/day (-28%; P < 0.0001) compared with placebo. In 40% and 50% of the individuals randomized to 81 or 325 mg/day aspirin, respectively, PGE-M reduction reached a threshold expected to prevent recurrence in 10% of individuals. These results support that aspirin significantly reduces elevated levels of PGE-M in those at increased colorectal cancer risk to levels consistent with lower risk for recurrent neoplasia and underscore the potential utility of PGE-M as a precision chemoprevention biomarker. The ASPIRED trial is registered as NCT02394769.

Published
2020

44. In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance

Author

Santilli, F., Zaccardi, F., Liani, R., Petrucci, Giovanna, Simeone, P., Pitocco, Dario, Tripaldi, R., Rizzi, Alessandro, Formoso, G., Pontecorvi, Alfredo, Angelucci, E., Pagliaccia, F., Golato, M., De Leva, Francesca, Vitacolonna, E., Rocca, Bianca, Consoli, A., Patrono, Carlo, Petrucci G. (ORCID:0000-0002-9280-3673), Pitocco D. (ORCID:0000-0002-6220-686X), Rizzi A., Pontecorvi A. (ORCID:0000-0003-0570-6865), De Leva F., Rocca B. (ORCID:0000-0001-8304-6423), Patrono C., Santilli, F., Zaccardi, F., Liani, R., Petrucci, Giovanna, Simeone, P., Pitocco, Dario, Tripaldi, R., Rizzi, Alessandro, Formoso, G., Pontecorvi, Alfredo, Angelucci, E., Pagliaccia, F., Golato, M., De Leva, Francesca, Vitacolonna, E., Rocca, Bianca, Consoli, A., Patrono, Carlo, Petrucci G. (ORCID:0000-0002-9280-3673), Pitocco D. (ORCID:0000-0002-6220-686X), Rizzi A., Pontecorvi A. (ORCID:0000-0003-0570-6865), De Leva F., Rocca B. (ORCID:0000-0001-8304-6423), and Patrono C.

Abstract

Background: Impaired glucose tolerance (IGT) is associated with increased cardiovascular morbidity and mortality. Enhanced thromboxane (TX)-dependent platelet activation plays a pivotal role in atherothrombosis and characterizes type 2 diabetes mellitus (DM). Whether this also pertains to IGT is currently unknown. We investigated whether TXA2-dependent platelet activation, as reflected by 11-dehydro-TXB2 (TXM) urinary excretion, is comparably abnormal in IGT as in DM, is persistent over long-term follow-up, changes as a function of metabolic disease progression, and is influenced by food intake. Methods: We prospectively investigated subjects with IGT (n = 48) and two control groups with DM diagnosed either less than 12 months (n = 60) or 12 months or more (n = 58). Results: Baseline TXM excretion was comparable between subjects with IGT and DM, with no evidence of a circadian variation. During a 36-month follow-up, urinary TXM excretion was stable over time in the DM groups, while tended to increase in subjects with IGT. Increasing urinary TXM excretion over time was observed in the subjects who progressed to diabetes vs nonprogressors. Conclusions: We conclude that TXA2-dependent platelet activation was at least as high in IGT as in patients with DM and further increased over time, especially in those who progressed to overt diabetes.

Published
2020

45. Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

Author

Walker, J, Cattaneo, M, Badimon, L, Agnelli, G, Chan, At, Lanas, A, Rocca, Bianca, Rothwell, P, Patrignani, P, Langley, R, Vilahur, G, Cosentino, F, Rocca, B (ORCID:0000-0001-8304-6423), Walker, J, Cattaneo, M, Badimon, L, Agnelli, G, Chan, At, Lanas, A, Rocca, Bianca, Rothwell, P, Patrignani, P, Langley, R, Vilahur, G, Cosentino, F, and Rocca, B (ORCID:0000-0001-8304-6423)

Abstract

At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.

Published
2020

46. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Author

Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., Huikuri, H. V., Johansson, I., Juni, P., Lettino, M., Marx, N., Mellbin, L. G., Ostgren, C. J., Rocca, Bianca, Roffi, M., Sattar, N., Seferovic, P. M., Sousa-Uva, M., Valensi, P., Wheeler, D. C., Piepoli, M. F., Birkeland, K. I., Adamopoulos, S., Ajjan, R., Avogaro, A., Baigent, C., Brodmann, M., Bueno, H., Ceconi, C., Chioncel, O., Coats, A., Collet, J. -P., Collins, P., Cosyns, B., Di Mario, C., Fisher, M., Fitzsimons, D., Halvorsen, S., Hansen, D., Hoes, A., Holt, R. I. G., Home, P., Katus, H. A., Khunti, K., Komajda, M., Lambrinou, E., Landmesser, U., Lewis, B. S., Linde, C., Lorusso, R., Mach, F., Mueller, C., Neumann, F. -J., Persson, F., Petersen, S. E., Petronio, A. S., Richter, D. J., Rosano, G. M. C., Rossing, P., Ryden, L., Shlyakhto, E., Simpson, I. A., Touyz, R. M., Wijns, W., Wilhelm, M., Williams, B., Windecker, S., Dean, V., Gale, C. P., Hindricks, G., Iung, B., Leclercq, C., Merkely, B., Zelveian, P. H., Scherr, D., Jahangirov, T., Lazareva, I., Shivalkar, B., Naser, N., Gruev, I., Milicic, D., Petrou, P. M., Linhart, A., Hildebrandt, P., Hasan-Ali, H., Marandi, T., Lehto, S., Mansourati, J., Kurashvili, R., Siasos, G., Lengyel, C., Thrainsdottir, I. S., Aronson, D., Di Lenarda, A., Raissova, A., Ibrahimi, P., Abilova, S., Trusinskis, K., Saade, G., Benlamin, H., Petrulioniene, Z., Banu, C., Magri, C. J., David, L., Boskovic, A., Alami, M., Liem, A. H., Bosevski, M., Svingen, G. F. T., Janion, M., Gavina, C., Vinereanu, D., Nedogoda, S., Mancini, T., Ilic, M. D., Fabryova, L., Fras, Z., Jimenez-Navarro, M. F., Norhammar, A., Lehmann, R., Mourali, M. S., Ural, D., Nesukay, E., Chowdhury, T. A., Rocca B. (ORCID:0000-0001-8304-6423), Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., Huikuri, H. V., Johansson, I., Juni, P., Lettino, M., Marx, N., Mellbin, L. G., Ostgren, C. J., Rocca, Bianca, Roffi, M., Sattar, N., Seferovic, P. M., Sousa-Uva, M., Valensi, P., Wheeler, D. C., Piepoli, M. F., Birkeland, K. I., Adamopoulos, S., Ajjan, R., Avogaro, A., Baigent, C., Brodmann, M., Bueno, H., Ceconi, C., Chioncel, O., Coats, A., Collet, J. -P., Collins, P., Cosyns, B., Di Mario, C., Fisher, M., Fitzsimons, D., Halvorsen, S., Hansen, D., Hoes, A., Holt, R. I. G., Home, P., Katus, H. A., Khunti, K., Komajda, M., Lambrinou, E., Landmesser, U., Lewis, B. S., Linde, C., Lorusso, R., Mach, F., Mueller, C., Neumann, F. -J., Persson, F., Petersen, S. E., Petronio, A. S., Richter, D. J., Rosano, G. M. C., Rossing, P., Ryden, L., Shlyakhto, E., Simpson, I. A., Touyz, R. M., Wijns, W., Wilhelm, M., Williams, B., Windecker, S., Dean, V., Gale, C. P., Hindricks, G., Iung, B., Leclercq, C., Merkely, B., Zelveian, P. H., Scherr, D., Jahangirov, T., Lazareva, I., Shivalkar, B., Naser, N., Gruev, I., Milicic, D., Petrou, P. M., Linhart, A., Hildebrandt, P., Hasan-Ali, H., Marandi, T., Lehto, S., Mansourati, J., Kurashvili, R., Siasos, G., Lengyel, C., Thrainsdottir, I. S., Aronson, D., Di Lenarda, A., Raissova, A., Ibrahimi, P., Abilova, S., Trusinskis, K., Saade, G., Benlamin, H., Petrulioniene, Z., Banu, C., Magri, C. J., David, L., Boskovic, A., Alami, M., Liem, A. H., Bosevski, M., Svingen, G. F. T., Janion, M., Gavina, C., Vinereanu, D., Nedogoda, S., Mancini, T., Ilic, M. D., Fabryova, L., Fras, Z., Jimenez-Navarro, M. F., Norhammar, A., Lehmann, R., Mourali, M. S., Ural, D., Nesukay, E., Chowdhury, T. A., and Rocca B. (ORCID:0000-0001-8304-6423)

Abstract

Guidelines

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results